Gullik Håkan Wickholm
Director/Board Member chez Beactica Therapeutics AB
Profil
Gullik Håkan Wickholm is currently a Director at Beactica Therapeutics AB and GHW Consulting AB.
Previously, he served as the Chief Executive Officer at Lytix Biopharma AS from 2014 to 2017.
He also worked as the Head-Regional Business Development at AstraZeneca.
AS and as a Director at Genovis AB.
Wickholm received his undergraduate degree from the University of Uppsala.
Postes actifs de Gullik Håkan Wickholm
| Sociétés | Poste | Début |
|---|---|---|
Beactica Therapeutics AB
 Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Director/Board Member | 01/01/2018 |
| GHW Consulting AB | Director/Board Member | - |
Anciens postes connus de Gullik Håkan Wickholm
| Sociétés | Poste | Fin |
|---|---|---|
| AstraZeneca AS | Corporate Officer/Principal | - |
| GENOVIS AB | Director/Board Member | - |
| LYTIX BIOPHARMA | Chief Executive Officer | 07/09/2017 |
Formation de Gullik Håkan Wickholm
| University of Uppsala | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENOVIS AB | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| Entreprise privées | 3 |
|---|---|
| AstraZeneca AS | |
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Distribution Services |
| GHW Consulting AB |
